Abstracts Archive - Page 1538 of 2607 - ACR Meeting Abstracts

Abstract Number: 2261 • 2017 ACR/ARHP Annual Meeting
Supporting Smoking Cessation in RA and SLE: Identifying Patient-Centered Outcomes
Aimée Wattiaux¹, Laura Block², Andrea Gilmore-Bykovskyi², Edmond Ramly³, Jane Sadusky⁴, Megan Piper⁵, Brittany Bettendorf⁶, Ann Rosenthal⁷ and Christie M. Bartels⁸, ¹Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²University of Wisconsin School of Nursing, Madison, WI, ³Industrial and Systems Engineering, University of Wisconsin College of Engineering, Madison, WI, ⁴Research Consultant, Madison, WI, ⁵University of Wisconsin Center for Tobacco Research and Intervention, Madison, WI, ⁶Rheumatology, Medical College of Wisconsin, MIlwaukee, WI, ⁷Division of Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ⁸Rheumatology/Medicine, University of Wisconsin - Madison, Madison, WI
Background/Purpose: Patients with RA and SLE are at higher risk for premature cardiovascular disease (CVD) than peers. Smoking is a leading modifiable risk factor for…
Abstract Number: 2262 • 2017 ACR/ARHP Annual Meeting
Knowledge, Beliefs and Concerns about Osteoporosis – a Qualitative Synthesis
Jude des Bordes¹, Seema Prasad², Gregory Pratt³, Maria Suarez-Almazor¹ and Maria A. Lopez-Olivo¹, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ²Gastroenterology Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ³Research Medical Library, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX
Background/Purpose: Educating patients with osteoporosis about bone health could increase their knowledge and self-efficacy. These can help them adopt healthy lifestyles to prevent osteoporosis-associated fractures.…
Abstract Number: 2263 • 2017 ACR/ARHP Annual Meeting
Obesity Independently Associates with Worse Patient Reported Outcomes in Women with Systemic Lupus Erythematosus
Sarah L. Patterson¹, Gabriela Schmajuk², Kashif Jafri³, Katherine D. Wysham³ and Patricia P. Katz⁴, ¹Division of Rheumatology, University of California, San Francisco, San Francisco, CA, ²San Francisco VA Medical Center, University of California San Francisco, San Francisco, CA, ³University of California, San Francisco, San Francisco, CA, ⁴Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Obesity has been shown to exacerbate systemic inflammation in the general population and contributes to worse disease-related outcomes in rheumatoid arthritis. The impact of…
Abstract Number: 2264 • 2017 ACR/ARHP Annual Meeting
Low Educational Attainment Is Associated with Poor Patient Status in Rheumatoid Arthritis (RA) or Osteoarthritis (OA) at the Initial Rheumatology Visit, with Remarkably Similar Patterns in Either Diagnosis
Juan Schmukler¹, Jacquelin R. Chua¹, Shakeel M. Jamal¹, Isabel Castrejón¹, Joel A Block¹ and Theodore Pincus², ¹Division of Rheumatology, Rush University Medical Center, Chicago, IL, ²Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Low educational attainment is associated with higher prevalence, morbidity, and mortality of many diseases, including rheumatoid arthritis1 (RA) and osteoarthritis2 (OA). These associations often…
Abstract Number: 2265 • 2017 ACR/ARHP Annual Meeting
Survey on Gout-Related Knowledge and Perception in Inpatient Setting on Hospitalized Patients with Gout
Roshanak Habibi¹, David T Liss², Sreelakshmi Panginikkod¹, Alvaro Altamirano Ufion³, Ehsan Rajabirostami¹ and Manish Jain⁴, ¹Internal Medicine, Presence Saint Francis Hospital, Evanston, IL, ²Northwestern University, Chicago, IL, ³Internal Medicine, Advocate Illinois Masonic Medical Center, Chicago, IL, ⁴Rheumatology, Presence Saint Francis Hospital, Evanston, IL
Background/Purpose: The increasing global burden of gout disease and its impact on the patient’s quality of life calls for new strategies in management. Even though…
Abstract Number: 2266 • 2017 ACR/ARHP Annual Meeting
Patient Knowledge, Attitudes, and Beliefs Regarding Biologic Therapies in Ankylosing Spondylitis (AS): Insights from a Large-Scale Analysis of Social Media Platforms
Deeba Minhas¹, Benjamin Noah², Eldin Dzubur², Christopher Almario³, Mariko Ishimori¹, Corey Arnold⁴, Amber Howard², Carine Khalil², Alma Jusufagic², Michelle Chen², Jina Park⁵, Michael Weisman¹ and Brennan Spiegel³, ¹Cedars-Sinai Medical Center Division of Rheumatology, Los Angeles, CA, ²Cedars-Sinai Center for Outcomes Research and Education (CS-CORE), Los Angeles, CA, ³Cedars-Sinai Center for Outcomes Research and Education (CS-CORE), Cedars-Sinai Medical Center Division of Digestive and Liver Diseases, Los Angeles, CA, ⁴Medical Imaging Informatics, Department of Radiology, University of California Los Angeles, Los Angeles, CA, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: While there are multiple biologic options for ankylosing spondylitis (AS), few attempts have been made to examine patients’ knowledge and understanding of these therapies…
Abstract Number: 2267 • 2017 ACR/ARHP Annual Meeting
Health Related Quality of Life in Lupus: Self-Management- a Modifiable Predictor
Kenneth Johnsen¹, Meenakshi Jolly² and Narender Annapureddy³, ¹Division of Rheumatology, Vanderbilt University Medical Center, Nashville, TN, ²Rush, Chicago, IL, ³Vanderbilt University Medical Center, Nashville, TN
Health Related Quality of Life in Lupus: Self-Management- a Modifiable Predictor. Background/Purpose: Health related quality of life (HRQOL) is significantly effected in patients with Lupus.…
Abstract Number: 2268 • 2017 ACR/ARHP Annual Meeting
Patient Perspectives from a Qualitative Study Predict Non-Adherence in Rheumatoid Arthritis
Valentin Ritschl^1,2, Angelika Lackner³, Carina Boström⁴, Michael Kundi⁵, Michaela Lehner⁶, Paul Studenic⁷, Winfried Graninger⁸, Josef S. Smolen⁹ and Tanja Stamm¹⁰, ¹Section for Outcomes Research, Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ²Section Occupational Therapy, Department Health Sciences, FH Campus Wien, Vienna, Austria, Vienna, Austria, ³Rheumatology and Immunology, Medical University Graz, Graz, Austria, Graz, Austria, ⁴Division of Physiotherapy, Department of Neurobiology, Karolinska Institutet, Huddinge, Sweden, Stockholm, Sweden, ⁵Center for Public Health, Department of Environmental Health, Medical University of Vienna, Vienna, Austria, 1090 Vienna, Austria, ⁶Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, 1090 Vienna, Austria, ⁷Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, ⁸Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ⁹Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ¹⁰Section for Outcomes Research, Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Vienna, Austria
Background/Purpose: In rheumatoid arthritis (RA), up to 80% of patients were found to be non-adherent to prescribed medication and non-pharmacological interventions. These patients do not…
Abstract Number: 2269 • 2017 ACR/ARHP Annual Meeting
The Meaningful Patient Engagement in Research Framework – an Empirically Based Conceptual Framework
Clayon Hamilton^1,2, Alison Hoens^1,2,3, Catherine L. Backman^4,5, Annette McKinnon⁶, Shanon McQuitty⁶, Kelly English⁶ and Linda Li⁴, ¹Physical Therapy, University of British Columbia, Vancouver, BC, Canada, ²Arthritis Research Canada, Richmond, BC, Canada, ³BC SUPPORT Unit, Vancouver, BC, Canada, ⁴Rheumatology, Arthritis Research Canada, Richmond, BC, Canada, ⁵Occupational Science & Occupational Therapy, The University of British Columbia, Vancouver, BC, Canada, ⁶Arthritis Patient Advisory Board, Arthritis Research Canada, Richmond, BC, Canada
Background/Purpose: Patient engagement in research is promoted to improve the relevance and quality of health research, but has little conceptualization derived from empirical data. To…
Abstract Number: 2270 • 2017 ACR/ARHP Annual Meeting
Identification of Optimal Subcutaneous Doses of Tocilizumab in Children with Polyarticular-Course Juvenile Idiopathic Arthritis
Hermine I. Brunner¹, Nicola Ruperto², Alberto Martini², Athimalaipet V. Ramanan³, Rubén Cuttica⁴, Jennifer E. Weiss⁵, Michael Henrickson¹, Heinrike Schmeling⁶, Jordi Anton⁷, Kirsten Minden⁸, Joy Hsu⁹, Kamal Bharucha¹⁰, Sunethra Wimalasundera¹¹, Alysha K. Kadva¹⁰, Ruchi Upmanyu¹¹, Navita L. Mallalieu⁹, Wendy Douglass¹¹, Daniel J Lovell¹ and Fabrizio De Benedetti¹², ¹Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati, OH, ²PRINTO Coordinating Centre, Genoa, Italy, ³Bristol Royal Hospital for Children, Bristol, United Kingdom, ⁴Hospital Gral de Niños Pedro Elizalde, Buenos Aires, Argentina, ⁵Hackensack University Medical Center, Hackensack, NJ, ⁶Alberta Children’s Hospital/University of Calgary, Calgary, AB, Canada, ⁷Hospital Sant Joan de Deu, Barcelona, Spain, ⁸Charité – University of Medicine Berlin, Berlin, Germany, ⁹Roche Innovation Center, New York, NY, ¹⁰Genentech, South San Francisco, CA, ¹¹Roche Products, Ltd., Welwyn Garden City, United Kingdom, ¹²Istituto Giannina Gaslini - Pediatria II, Reumatologia - PRINTO, Genoa, Italy
Background/Purpose: The efficacy and safety of intravenous (IV) tocilizumab (TCZ), an interleukin-6 receptor-alpha inhibitor, have been demonstrated in patients with polyarticular-course juvenile idiopathic arthritis (pcJIA)…
Abstract Number: 2271 • 2017 ACR/ARHP Annual Meeting
Safety of Adalimumab±Methotrexate for the Treatment of Polyarticular Juvenile Idiopathic Arthritis (pJIA)
Hermine I. Brunner¹, Nicola Ruperto², Kabita Nanda³, Mary Toth⁴, Ivan Foeldvari⁵, John F. Bohnsack⁶, Diana Milojevic⁷, C. Egla Rabinovich⁸, Daniel J Kingsbury⁹, Katherine Marzan¹⁰, Pierre Quartier¹¹, Kirsten Minden¹², Elizabeth Chalom¹, Gerd Horneff¹³, Rolf M. Kuester¹⁴, Jason A Dare¹⁵, Mareike Bereswill¹⁶, Jasmina Kalabic¹⁶, Hartmut Kupper¹⁶, Daniel J Lovell¹ and Alberto Martini², ¹PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²PRINTO-IRCCS Gaslini, Genova, Italy, ³University of Washington School of Medicine and Seattle Children's Hospital, Bayside, NY, ⁴Akron Children's Hospital, Akron, OH, ⁵Department of Pediatric Rheumatology, Hamburger Zentrum für Kinder und Jugendrheumatologie, Hamburg, Germany, ⁶University of Utah, Department of Pediatrics, Salt Lake City, UT, ⁷The Floating Hospital for Children at Tufts Medical Center, Boston, MA, ⁸Duke University Medical Center, Durham, NJ, ⁹Randall Children’s Hospital at Legacy Emanuel, Portland, OR, ¹⁰Children's Hospital Los Angeles, Los Angeles, CA, ¹¹Hopital Necker-Enfants Malades, Paris, France, ¹²Kinderklinik der Charite, Otto-Heubner Centrum, Berlin, Germany, ¹³Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ¹⁴Orthopädiezentrum Altona, Hamburg, Germany, ¹⁵Arkansas Children’s Hospital, Little Rock, AR, ¹⁶AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
Background/Purpose: JIA is the most common chronic inflammatory rheumatic disease of childhood. Due to their known safety and efficacy, TNF inhibitors are used for long-term…
Abstract Number: 2272 • 2017 ACR/ARHP Annual Meeting
Long-Term Effectiveness and Safety of Abatacept in Juvenile Idiopathic Arthritis: Ongoing Results from the Abatacept in JIA Registry
Daniel J Lovell¹, N Ruperto², N Tzaribachev³, A Zeft⁴, Rolando Cimaz⁵, V Stanevica⁶, Gerd Horneff⁷, John F. Bohnsack⁸, Thomas A. Griffin⁹, R Carrasco¹⁰, Maria Trachana¹¹, Jason A Dare¹², I Foeldvari¹³, Richard K Vehe¹⁴, TA Simon¹⁵, Hermine I. Brunner¹⁶ and Alberto Martini², ¹Cincinnati Children’s Hosp. Medical Center, Cincinnati, OH, ²Istituto G. Gaslini Pediatria II Reumatologia, Genova, Italy, ³University Medical Center Schleswig-Holstein, Bad Bramstedt, Germany, ⁴Cleveland Clinic, Cleveland, OH, ⁵Azienda Ospedaliero-Universitaria Meyer, Florence, Italy, ⁶Riga Stradins University, Riga, Latvia, ⁷Asklepios Klinik Zentrum für Allgemeine Paediatrie und Neonatologie, Sankt Augustin, Germany, ⁸University of Utah School of Medicine, Salt Lake City, UT, ⁹Levine Children’s Hospital at Carolinas Medical Center, Charlotte, NC, ¹⁰Specially For Children, Austin, TX, ¹¹Hippokration General Hospital, Thessaloniki, Greece, ¹²University of Arkansas for Medical Sciences, Little Rock, AR, ¹³Hamburg Centre for Pediatric Rheumatology, Hamburg, Germany, ¹⁴University of Minnesota, Minneapolis, MN, ¹⁵Bristol-Myers Squibb, Princeton, NJ, ¹⁶Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Abatacept is an FDA- and EMA-approved biologic that is widely used in children with juvenile idiopathic arthritis (JIA). The purpose of this long-term ongoing…
Abstract Number: 2273 • 2017 ACR/ARHP Annual Meeting
An Open-Label Extension Study to Assess the Long-Term Safety of Etanercept in Pediatric Patients with Extended Oligo, Enthesitis Related, and Psoriatic Juvenile Idiopathic Arthritis: 6-Year Data from the Clipper Studies
Ivan Foeldvari¹, Tamas Constantin¹, Jelena Vojinovic², Gerd Horneff¹, Joke Dehoorne¹, Gordana Susic¹, Katarzyna Kobusinska¹, Violeta Vladislava Panaviene¹, Zbigniew Zuber¹, Valda Stanevicha¹, Vyacheslav Chasnyk¹, Ronald Pedersen³, Jack F Bukowski⁴, Tina Hinnershitz⁵, Bonnie Vlahos⁶, Alberto Martini¹ and Nicolino Ruperto¹, ¹Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ²Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Jersey, ³Department of Biostatistics, Pfizer, Collegeville, PA, ⁴Clinical Affairs, Pfizer, Collegeville, PA, ⁵Specialty Care MDG, Pfizer, Collegeville, PA, ⁶Clinical Sciences, Pfizer, Collegeville, PA
Background/Purpose: A Phase 3b, open-label (OL), multicenter study (CLIPPER) has shown the safety of etanercept (ETN) in pediatric patients (pts) with extended oligoarticular (eo) juvenile…
Abstract Number: 2274 • 2017 ACR/ARHP Annual Meeting
Risk of Serious Events, Serious Infections, Uveitis, Crohn’s Disease, Colitis and Malignancies in Patients with Juvenile Idiopathic Arthritis on Continuous Treatment with Etanercept over Time: A Report from a Biologics Registry
Gerd Horneff¹, Frank Weller-Heinemann², Toni Hospach³, Prasad Oommen⁴, Gerd Ganser⁵, Johannes Peter Haas⁶, K Minden⁷ and Ariane Klein⁸, ¹Asklepios Clinic, Sankt Augustin, Germany, ²PRINTO, Genoa, Italy, ³Pediatrics, Olgahospital, Klinikum Stuttgart, Stuttgard, Germany, ⁴University Duesseldorf, Duesseldorf, Germany, ⁵Pediatric Rheumatology, Sankt Josef Stift Sendenhorst, Sendenhorst, Germany, ⁶Centre for Pediatric Rheumatology Garmisch-Partenkirchen, Garmisch-Partenkirchen, Germany, ⁷Charité – University of Medicine Berlin, Berlin, Germany, ⁸Center of Pediatrics and Neonatology, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany
Background/Purpose: To investigate changes in the risk for adverse events of special interest in juvenile idiopathic arthritis (JIA) patients treated with Etanercept documented in the…
Abstract Number: 2275 • 2017 ACR/ARHP Annual Meeting
Factors Related to Sustained Discontinuation of Medications for Well-Controlled JIA in the Childhood Arthritis & Rheumatology Research Alliance Registry
Daniel B. Horton¹, Fenglong Xie², Melissa L. Mannion³, Sarah Ringold⁴, Colleen K. Correll⁵, Anne C. Dennos⁶ and Timothy Beukelman⁷, ¹Rutgers Biomedical and Health Sciences, New Brunswick, NJ, ²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Pediatric rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Seattle Children's Hospital, Seattle, WA, ⁵Pediatrics, University of Minnesota, Minneapolis, MN, ⁶Duke Clinical Research Institute, Durham, NC, ⁷Pediatrics, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Stopping medications is a priority for many patients with well-controlled JIA, but few factors predict favorable outcomes after discontinuation. We examined factors associated with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].